| Literature DB >> 29781505 |
Karine Lascelles1,2, Shazia Afridi2, Ata Siddiqui1, Cheryl Hemingway3, Rosalie Ferner2, Vijeya Ganesan3,4.
Abstract
Unlike adult neurofibromatosis type 2 (NF2), which presents with symptoms related to bilateral vestibular schwannomas, children with NF2 most frequently present with ocular, dermatological, and neurological symptoms. Arteriopathy, a well-established feature in neurofibromatosis type 1, is not a widely recognized feature of NF2. Here we report three children with NF2 with cerebral arteriopathy and/or arterial ischaemic stroke. Bevacizumab, a vascular endothethial growth factor inhibitor, is an established treatment for rapidly growing vestibular schwannomas; however, it carries a risk of both ischaemic and haemorrhagic stroke. Thus, the role of screening and risk to benefit ratio of bevacizumab in NF2 merit further consideration. WHAT THIS PAPER ADDS: Children with neurofibromatosis type 2 (NF2) may be at increased risk of cerebral vasculopathy and arterial ischaemic stroke. Targeted magnetic resonance angiography should be performed in children with NF2 who are being considered for bevacizumab therapy.Entities:
Mesh:
Year: 2018 PMID: 29781505 DOI: 10.1111/dmcn.13920
Source DB: PubMed Journal: Dev Med Child Neurol ISSN: 0012-1622 Impact factor: 5.449